List of Venlafaxine Besylate drug patents
Venlafaxine Besylate is owned by Almatica.
Venlafaxine Besylate contains Venlafaxine Besylate.
Venlafaxine Besylate has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Venlafaxine Besylate are:
- US6717015
Venlafaxine Besylate was authorised for market use on 29 June, 2022.
Venlafaxine Besylate is available in tablet, extended release;oral dosage forms.
Venlafaxine Besylate can be used as treatment of depression and generalized anxiety disorder.
The generics of Venlafaxine Besylate are possible to be released after 16 May, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6717015 | ALMATICA | Venlafaxine besylate |
Mar, 2023
(2 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776358 | ALMATICA | Extended release venlafaxine besylate tablets |
May, 2028
(4 years from now) | |
Drugs and Companies using VENLAFAXINE BESYLATE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: Treatment of depression and generalized anxiety disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
VENLAFAXINE BESYLATE family patents
4
United States
2
European Union
1
South Africa
1
Argentina
1
Australia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic